ÂÜÀòÂÒÂ×

Huw Nash serves as the Chief Operating Officer and Chief Business Officer at Stoke Therapeutics since October 2014, focusing on developing antisense oligonucleotide medicines for rare diseases. Prior to this role, Huw Nash was the Chief Executive Officer at Stoke Therapeutics, emphasizing the same therapeutic innovations. Huw Nash has also been an Entrepreneur in Residence at Apple Tree Partners since October 2014 and at the Wyss Institute for Biologically Inspired Engineering from June 2014 to September 2014. Huw Nash's career includes a consultancy position with the Novartis Venture Fund, a co-founding role and Vice President of Corporate Development at Aileron Therapeutics, where $62 million in venture investments were raised, as well as experience as Founding Scientist and Vice President of External Collaborations at NeoGenesis Pharmaceuticals. Huw Nash holds a Doctor of Philosophy in Organic Chemistry and a Bachelor of Arts in Biochemistry, both from Harvard University.